Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism.

@article{Westermann2007ContributionsOI,
  title={Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism.},
  author={Dirk Westermann and Susanne Rutschow and Sebastian Jaeger and Anne Linderer and Stefan D. Anker and A. R. Riad and Thomas Unger and Heinz-Peter Schultheiss and Matthias Pauschinger and Carsten Tsch{\"o}pe},
  journal={Diabetes},
  year={2007},
  volume={56 3},
  pages={641-6}
}
We investigated the effect of the angiotensin type 1 (AT-1) receptor antagonist, irbesartan, on matrix metalloproteinase (MMP) activity and cardiac cytokines in an animal model of diabetic cardiomyopathy. Diabetes was induced in 20 C57/bl6 mice by injection of streptozotocin (STZ). These animals were treated with irbesartan or placebo and were compared with nondiabetic controls. Left ventricular (LV) function was measured by pressure-volume loops with parameters for systolic function (end… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 93 extracted citations

Similar Papers

Loading similar papers…